226 related articles for article (PubMed ID: 28933554)
21. Biomimetic, synthetic HDL nanostructures for lymphoma.
Yang S; Damiano MG; Zhang H; Tripathy S; Luthi AJ; Rink JS; Ugolkov AV; Singh AT; Dave SS; Gordon LI; Thaxton CS
Proc Natl Acad Sci U S A; 2013 Feb; 110(7):2511-6. PubMed ID: 23345442
[TBL] [Abstract][Full Text] [Related]
22. MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma.
Wang WG; Liu ZB; Jiang XN; Lee J; Zhou XY; Li XQ
Histopathology; 2017 Nov; 71(5):778-785. PubMed ID: 28639315
[TBL] [Abstract][Full Text] [Related]
23. Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia.
McMahon KM; Scielzo C; Angeloni NL; Deiss-Yehiely E; Scarfo L; Ranghetti P; Ma S; Kaplan J; Barbaglio F; Gordon LI; Giles FJ; Thaxton CS; Ghia P
Oncotarget; 2017 Feb; 8(7):11219-11227. PubMed ID: 28061439
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.
Wang WG; Jiang XN; Sheng D; Sun CB; Lee J; Zhou XY; Li XQ
Lab Invest; 2019 Oct; 99(10):1418-1427. PubMed ID: 31197205
[TBL] [Abstract][Full Text] [Related]
25. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation.
Singh RR; Kim JE; Davuluri Y; Drakos E; Cho-Vega JH; Amin HM; Vega F
Leukemia; 2010 May; 24(5):1025-36. PubMed ID: 20200556
[TBL] [Abstract][Full Text] [Related]
26. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.
Yao S; Xu F; Chen Y; Ge Y; Zhang F; Huang H; Li L; Lin D; Luo X; Xu J; Luo D; Zhu X; Liu Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):10. PubMed ID: 28069035
[TBL] [Abstract][Full Text] [Related]
27. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.
Fontan L; Goldstein R; Casalena G; Durant M; Teater MR; Wilson J; Phillip J; Xia M; Shah S; Us I; Shinglot H; Singh A; Inghirami G; Melnick A
Blood; 2021 Feb; 137(6):788-800. PubMed ID: 32785655
[TBL] [Abstract][Full Text] [Related]
28. SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker.
Wu W; Lu P; Patel P; Ma J; Cai KQ; Mallikarjuna VS; Poureghbali S; Nakhoda SR; Nejati R; Lynn Wang Y
Oncogene; 2023 Feb; 42(6):409-420. PubMed ID: 36482202
[TBL] [Abstract][Full Text] [Related]
29. Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features.
Wang WG; Cui WL; Wang L; Zhu F; Wan XC; Ping B; Zhou XY; Li XQ
Am J Surg Pathol; 2015 Jul; 39(7):902-11. PubMed ID: 25970684
[TBL] [Abstract][Full Text] [Related]
30. DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.
Chang S; Li B; Xie Y; Wang Y; Xu Z; Jin S; Yu D; Wang H; Lu Y; Zhang Y; Ma R; Huang C; Lai W; Wu X; Zhu W; Shi J
Neoplasia; 2022 Jan; 24(1):50-61. PubMed ID: 34890905
[TBL] [Abstract][Full Text] [Related]
31. Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.
Young RM; Phelan JD; Wilson WH; Staudt LM
Immunol Rev; 2019 Sep; 291(1):190-213. PubMed ID: 31402495
[TBL] [Abstract][Full Text] [Related]
32. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.
Xu W; Berning P; Lenz G
Blood; 2021 Sep; 138(13):1110-1119. PubMed ID: 34320160
[TBL] [Abstract][Full Text] [Related]
33. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
34. Biomimetic Magnetic Nanostructures: A Theranostic Platform Targeting Lipid Metabolism and Immune Response in Lymphoma.
Singh A; Nandwana V; Rink JS; Ryoo SR; Chen TH; Allen SD; Scott EA; Gordon LI; Thaxton CS; Dravid VP
ACS Nano; 2019 Sep; 13(9):10301-10311. PubMed ID: 31487458
[TBL] [Abstract][Full Text] [Related]
35. Scavenger Receptor Type B1 and Lipoprotein Nanoparticle Inhibit Myeloid-Derived Suppressor Cells.
Plebanek MP; Bhaumik D; Bryce PJ; Thaxton CS
Mol Cancer Ther; 2018 Mar; 17(3):686-697. PubMed ID: 29282300
[TBL] [Abstract][Full Text] [Related]
36. The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma.
Bongero D; Paoluzzi L; Marchi E; Zullo KM; Neisa R; Mao Y; Escandon R; Wood K; O'Connor OA
Leuk Lymphoma; 2015; 56(10):2945-52. PubMed ID: 25860245
[TBL] [Abstract][Full Text] [Related]
37. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.
Kuo HP; Ezell SA; Hsieh S; Schweighofer KJ; Cheung LW; Wu S; Apatira M; Sirisawad M; Eckert K; Liang Y; Hsu J; Chen CT; Beaupre D; Chang BY
Am J Cancer Res; 2016; 6(11):2489-2501. PubMed ID: 27904766
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin II promotes selective uptake of high density lipoprotein cholesterol esters in bovine adrenal glomerulosa and human adrenocortical carcinoma cells through induction of scavenger receptor class B type I.
Cherradi N; Bideau M; Arnaudeau S; Demaurex N; James RW; Azhar S; Capponi AM
Endocrinology; 2001 Oct; 142(10):4540-9. PubMed ID: 11564720
[TBL] [Abstract][Full Text] [Related]
39. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
[TBL] [Abstract][Full Text] [Related]
40. Selective delivery of T22-PE24-H6 to CXCR4
Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
